Drug Trial Radar · NCT02629848
Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Dec 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
401
Actual
Start
Jul 2012
Primary completion
Sep 2014
Study completion Mar 2015
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 14, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate progression free survival (PFS), overall survival (OS), objective response rate (ORR), duration of response, and safety of motesanib (AMG706) in combination with paclitaxel and carboplatin compared to placebo in combination with paclitaxel and carboplatin.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
MotesanibDrug
Motesanib (AMG 706) 5 x 25 mg tablets
PlaceboDrug
Motesanib placebo-matching tablets
PaclitaxelDrug
Paclitaxel IV
CarboplatinDrug
Carboplatin IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: Up to 24 Months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.